Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...
King Abdul Aziz Medical City, Riyadh, Central, Saudi Arabia
The Johns Hopkins Institute for Clinical and Translational Research, Baltimore, Maryland, United States
Research Site, Krakow, Poland
Profil Institute for Metabolic Research, Neuss, NRW, Germany
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Translational Pain Research, Brigham and Women's Hospital, Boston, Massachusetts, United States
DMI Research, Pinellas, Florida, United States
Cyn3rgy Research, Gresham, Oregon, United States
Clinical Research Associates Incorporated, Nashville, Tennessee, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Ru-Band Lu, Tainan, Taiwan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.